JP2016507521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507521A5 JP2016507521A5 JP2015555498A JP2015555498A JP2016507521A5 JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5 JP 2015555498 A JP2015555498 A JP 2015555498A JP 2015555498 A JP2015555498 A JP 2015555498A JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- sequence shown
- disease
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000023732 binding proteins Human genes 0.000 claims 31
- 108091008324 binding proteins Proteins 0.000 claims 31
- 102100035793 CD83 antigen Human genes 0.000 claims 30
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 3
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000005965 immune activity Effects 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759780P | 2013-02-01 | 2013-02-01 | |
| US61/759,780 | 2013-02-01 | ||
| PCT/AU2014/000066 WO2014117220A1 (en) | 2013-02-01 | 2014-01-31 | Anti-cd83 antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000340A Division JP2019076102A (ja) | 2013-02-01 | 2019-01-04 | 抗ｃｄ８３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507521A JP2016507521A (ja) | 2016-03-10 |
| JP2016507521A5 true JP2016507521A5 (OSRAM) | 2017-02-23 |
| JP6539585B2 JP6539585B2 (ja) | 2019-07-03 |
Family
ID=51261317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555498A Active JP6539585B2 (ja) | 2013-02-01 | 2014-01-31 | 抗ｃｄ８３抗体及びその使用 |
| JP2019000340A Pending JP2019076102A (ja) | 2013-02-01 | 2019-01-04 | 抗ｃｄ８３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000340A Pending JP2019076102A (ja) | 2013-02-01 | 2019-01-04 | 抗ｃｄ８３抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9840559B2 (OSRAM) |
| EP (2) | EP3626743A1 (OSRAM) |
| JP (2) | JP6539585B2 (OSRAM) |
| KR (2) | KR102204127B1 (OSRAM) |
| CN (1) | CN105531289B (OSRAM) |
| AU (1) | AU2014213009B2 (OSRAM) |
| CA (1) | CA2899960C (OSRAM) |
| DK (1) | DK2951208T3 (OSRAM) |
| ES (1) | ES2762622T3 (OSRAM) |
| MX (1) | MX2015010023A (OSRAM) |
| NZ (1) | NZ711543A (OSRAM) |
| PT (1) | PT2951208T (OSRAM) |
| WO (1) | WO2014117220A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2951208T (pt) | 2013-02-01 | 2019-12-30 | Univ California | Anticorpos anti-cd83 e sua utilização |
| CA2965170A1 (en) * | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
| WO2019051541A1 (en) * | 2017-09-13 | 2019-03-21 | Dendrocyte Biotech Pty Ltd | Treatment method |
| US12492254B2 (en) * | 2018-02-23 | 2025-12-09 | H. Lee Moffitt Cancer Center and Research Intitute. Inc. | CD83-binding chimeric antigen receptors |
| AU2020315878A1 (en) | 2019-07-19 | 2022-03-03 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
| JP7701908B2 (ja) * | 2019-08-16 | 2025-07-02 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞 |
| CN117547553A (zh) * | 2023-11-21 | 2024-02-13 | 中国人民解放军陆军特色医学中心 | Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4593089A (en) | 1980-07-30 | 1986-06-03 | Abbott Laboratories | Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4751190A (en) | 1985-07-22 | 1988-06-14 | Abbott Laboratories | Fluorescence polarization immunoassay and reagents for use therein |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| ATE82588T1 (de) | 1986-04-28 | 1992-12-15 | Endotronics Inc | Zuchtverfahren fuer leukocyten. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| DE4211351A1 (de) | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
| AU3691093A (en) | 1992-04-14 | 1993-10-21 | Hybritech Incorporated | Methods of inhibiting the growth of multidrug resistant tumors |
| US5710262A (en) | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
| US5316920A (en) | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| US20080152586A1 (en) | 1992-09-25 | 2008-06-26 | Avipep Pty Limited | High avidity polyvalent and polyspecific reagents |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6541213B1 (en) | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| CA2244326C (en) | 1997-08-11 | 2006-03-28 | Shinichi Eda | Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6562622B1 (en) | 1998-05-08 | 2003-05-13 | Diatech Pty, Ltd | Continuous in vitro evolution |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000042430A1 (en) | 1999-01-15 | 2000-07-20 | Medtox Scientific, Inc. | Lateral flow test strip |
| CN1367688A (zh) * | 1999-04-14 | 2002-09-04 | 美国政府卫生与公众服务部 | 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物 |
| US7270969B2 (en) | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| EP1419387B1 (en) | 2001-08-20 | 2012-01-04 | Proteome Systems Ltd. | Diagnostic testing process |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| WO2003045318A2 (en) * | 2001-11-21 | 2003-06-05 | Celltech R & D, Inc. | Manipulation of cytokine levels using cd83 gene products |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2002950779A0 (en) | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP2258724A1 (en) | 2002-11-21 | 2010-12-08 | Celltech R & D, Inc. | Modulating immune responses using multimerized anti-CD83 antibodies |
| US20040265926A1 (en) | 2002-11-21 | 2004-12-30 | Leong Ng | Bodily fluid markers of tissue hypoxia |
| US7169898B2 (en) * | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| WO2004108158A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-cd3 antibody |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| BRPI0416262B1 (pt) | 2003-11-05 | 2022-04-12 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス， インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| US20090247455A1 (en) | 2005-03-31 | 2009-10-01 | Mark Fear | Isolation of Inhibitors of IRES-Mediated Translation |
| KR20160045151A (ko) * | 2005-04-08 | 2016-04-26 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
| KR20080068004A (ko) | 2005-08-15 | 2008-07-22 | 아라나 테라퓨틱스 리미티드 | 뉴 월드 영장류 구조형성영역을 가진 조작 항체 |
| CA2690973A1 (en) * | 2006-06-23 | 2007-12-27 | Paul M. Simon | Targeted immune conjugates |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| WO2009157623A1 (en) | 2008-06-25 | 2009-12-30 | Korea Research Institute Of Bioscience And Biotechnology | Cd9-specific human antibodies |
| AR074369A1 (es) | 2008-11-20 | 2011-01-12 | Genentech Inc | Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso |
| US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| PT2951208T (pt) | 2013-02-01 | 2019-12-30 | Univ California | Anticorpos anti-cd83 e sua utilização |
| CA2965170A1 (en) | 2014-10-23 | 2016-04-28 | Dendrocyte Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
| WO2019051541A1 (en) | 2017-09-13 | 2019-03-21 | Dendrocyte Biotech Pty Ltd | Treatment method |
-
2014
- 2014-01-31 PT PT147456370T patent/PT2951208T/pt unknown
- 2014-01-31 EP EP19203675.4A patent/EP3626743A1/en not_active Withdrawn
- 2014-01-31 ES ES14745637T patent/ES2762622T3/es active Active
- 2014-01-31 CA CA2899960A patent/CA2899960C/en active Active
- 2014-01-31 CN CN201480011458.5A patent/CN105531289B/zh active Active
- 2014-01-31 AU AU2014213009A patent/AU2014213009B2/en not_active Ceased
- 2014-01-31 WO PCT/AU2014/000066 patent/WO2014117220A1/en not_active Ceased
- 2014-01-31 DK DK14745637.0T patent/DK2951208T3/da active
- 2014-01-31 NZ NZ711543A patent/NZ711543A/en not_active IP Right Cessation
- 2014-01-31 EP EP14745637.0A patent/EP2951208B1/en active Active
- 2014-01-31 MX MX2015010023A patent/MX2015010023A/es active IP Right Grant
- 2014-01-31 US US14/765,236 patent/US9840559B2/en active Active
- 2014-01-31 JP JP2015555498A patent/JP6539585B2/ja active Active
- 2014-01-31 KR KR1020157023660A patent/KR102204127B1/ko not_active Expired - Fee Related
- 2014-01-31 KR KR1020207029681A patent/KR102449868B1/ko active Active
-
2017
- 2017-11-09 US US15/808,423 patent/US10781255B2/en active Active
-
2019
- 2019-01-04 JP JP2019000340A patent/JP2019076102A/ja active Pending
-
2020
- 2020-07-09 US US16/924,860 patent/US11725054B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| JP2016507521A5 (OSRAM) | ||
| JP2023071684A (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2012501670A5 (OSRAM) | ||
| CN112955470A (zh) | 抗tnfr2抗体及其用途 | |
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| TW201031421A (en) | IL-1 binding proteins | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| JP2012526558A5 (OSRAM) | ||
| KR20180083944A (ko) | 항체 및 이의 사용 방법 | |
| TW201134487A (en) | Therapeutic DLL4 binding proteins | |
| JP2017530119A (ja) | リンパ球における阻害経路の中和 | |
| KR20120104542A (ko) | Ｉｌ?１ 결합 단백질 | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| US12071479B2 (en) | Antibodies against ILT2 and use thereof | |
| CN114555637A (zh) | 针对ilt2的抗体及其用途 | |
| CN113278071B (zh) | 抗人干扰素α受体1单克隆抗体及其应用 | |
| CA3172120A1 (en) | Chimeric antigen receptor specific for human cd45rc and uses thereof | |
| US20240010751A1 (en) | Multispecific binding agents and uses thereof | |
| CN109071660A (zh) | 预防移植物抗宿主疾病的方法 | |
| WO2022031680A1 (en) | Cd47 binding agents and uses thereof | |
| US20230303699A1 (en) | Pd-l1 binding agents and uses thereof | |
| JP2024512252A (ja) | Ｃｄ４７に対する単一ドメイン抗体及びその用途 | |
| CN118401563A (zh) | 抗gucy2c纳米抗体及其应用 | |
| HK1229347A1 (en) | Therapeutic dll4 binding proteins |